A Case of Successful Danazol Therapy in Autoimmune Thrombocytopenia Associated with Systemic Lupus Erythematosus.
- Author:
Kyung Min KIM
1
;
Byeong Seon LEE
;
Young Seo PARK
Author Information
1. Department of Pediatrics, College of Medicine, Ulsan University, Seoul, Korea. yspark@www.amc.seoul.com
- Publication Type:Case Report
- Keywords:
Danazol;
Autoimmune thrombocytopenia;
Systemic lupus erythematosus
- MeSH:
Adrenal Cortex Hormones;
Anemia, Hemolytic, Autoimmune;
Danazol*;
Humans;
Immunoglobulins;
Lupus Erythematosus, Systemic*;
Purpura, Thrombocytopenic, Idiopathic*;
Splenectomy
- From:Journal of the Korean Pediatric Society
2001;44(11):1330-1333
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Autoimmune thrombocytopenia and autoimmune hemolytic anemia occur in 10-26% of patients with systemic lupus erythematosus(SLE). These hematological manifestations may be the sole presenting sign and can precede the appearance of diagnosable SLE in 5 to 23% of cases. The conventional treatment for SLE associated with these disorders includes corticosteroid therapy and splenectomy, but autoimmune thrombocytopenia or autoimmune hemolytic anemia may be refractory to both treatments. We experienced a case of a SLE patient complicated by severe autoimmune thrombocytopenia. Therapy with intravenous immunoglobulin and corticosteroids failed. She responded to danazol and remission of thrombocytopenia(platelet >100,000/mm3) was observed 7 days after starting danazol. Danazol therapy seems to be a useful and well tolerated treatment for refractory autoimmune thrombocytopenia associated with SLE.
